Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LEGN
SELLLegend Biotech Corporation · Healthcare · United States · $4.3B · Avg Vol: $52M/d
COMPANY DESCRIPTION
Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies, primarily CAR-T treatments for oncology. The company's core asset is Carvykti, a potentially transformative CAR-T therapy for multiple myeloma, developed in partnership with Janssen. Its competitive advantage lies in its proprietary cell therapy platform and advanced pipeline, positioning it as a leading innovator in the rapidly evolving and high-potential field of cellular immunotherapy.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 117.0M | 285.1M | 627.3M | 1.0B | 106.4% | 1.1B | 1.4B | 1.8B | 32.9% |
| EPS | -2.80 | -2.94 | -0.96 | -1.62 | — | -1.44 | — | — | — |
| Shares | 330.1M | 363.8M | 367.3M | 369.9M | +12.0% | — | — | — | — |
| Debt | 284.5M | 328.7M | 350.6M | 413.7M | 13.3% | 389.3M | — | — | — |
| Equity | 744.3M | 1.3B | 1.0B | 1.0B | 10.4% | — | — | — | — |
| Op CF | -201.3M | -393.3M | -144.0M | -100.2M | — | -81.7M | — | — | — |
| Inv CF | -77.1M | 92.9M | -850.6M | 709.6M | — | — | — | — | — |
| Fin CF | 378.0M | 791.4M | 5.7M | -0.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LEGN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LEGN | Legend Biotech Corporation(you) | $4.3B | 27 | SELL |
| CAI | Caris Life Sciences, Inc. | $4.4B | 27 | SELL |
| TNGX | Tango Therapeutics, Inc. | $4.3B | 29 | SELL |
| EWTX | Edgewise Therapeutics, Inc. | $4.4B | 30 | SELL |
| IDYA | IDEAYA Biosciences, Inc. | $3.4B | 27 | SELL |
| DNLI | Denali Therapeutics Inc. | $3.7B | 24 | SELL |
| RLAY | Relay Therapeutics, Inc. | $4.0B | 31 | SELL |
| VKTX | Viking Therapeutics, Inc. | $4.0B | 20 | SELL |
| RCUS | Arcus Biosciences, Inc. | $3.6B | 22 | SELL |
| ALMS | Alumis Inc. | $3.6B | 22 | SELL |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%